Anticancer evaluation of methotrexate and curcumin-coencapsulated niosomes against colorectal cancer cell lines-Reference-Cited by-同舟云学术

Anticancer evaluation of methotrexate and curcumin-coencapsulated niosomes against colorectal cancer cell lines

Published:2022-02 Issue:4 Volume:17 Page:201-217
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Mousazadeh Navid¹²^ORCID,Gharbavi Mahmoud¹³^ORCID,Rashidzadeh Hamid¹⁴^ORCID,Nosrati Hamed¹⁵^ORCID,Danafar Hossein⁴⁶^ORCID,Johari Behrooz¹²^ORCID

Affiliation:

1. Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

2. Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

3. Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4. Department of Pharmaceutical Biomaterials, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

5. Joint Ukraine-Azerbaijan International Research & Education Center of Nanobiotechnology & Functional Nanosystems, Drohobych, Ukraine, Baku, Azerbaijan

6. Zanjan Pharmaceutical Biotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

Abstract

Aim: The aim of the present investigation was to develop niosomes containing both curcumin (CUR) and methotrexate (MTX). Also, the combinational effect of CUR and MTX in both free and niosomal forms on growth inhibition potential and induction of apoptosis in the HCT-116 cell line were exploited. Materials & methods: Niosomes were prepared by the thin-film hydration method and their physicochemical properties were determined by various techniques. Cellular uptake, cell apoptosis, wound healing and MTT assay were conducted to ascertain niosomes' feasibility for cancer therapy. Results: The combination of CUR and MTX in niosomal formulation showed more toxicity than their combination in free form. Conclusion: The nanocarrier-based approach was effective for the codelivery of CUR and MTX against cancer cells in vitro.

Funder

Zanjan University of Medical Sciences

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2021-0334

Reference58 articles.

1. Global colorectal cancer burden in 2020 and projections to 2040

2. Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer

3. Nanovectors Design for Theranostic Applications in Colorectal Cancer